抗β2糖蛋白I（β2GPI）自身抗体识别β2GPI第一结构域上的一个表位。
Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.
作者信息
Iverson G M, Victoria E J, Marquis D M
机构信息
La Jolla Pharmaceutical Company, San Diego, CA 92121, USA.
出版信息
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15542-6. doi: 10.1073/pnas.95.26.15542.
Anticardiolipin (aCL) autoantibodies are associated with thrombosis, recurrent fetal loss, and thrombocytopenia. Only aCL found in autoimmune disease require the participation of the phospholipid binding plasma protein beta2 glycoprotein I (beta2GPI) for antibody binding and now are called anti-beta2GPI. The antigenic specificity of aCL affinity purified from 11 patients with high titers was evaluated in an effort to better understand the pathophysiology associated with aCL. Seven different recombinant domain-deleted mutants of human beta2GPI, and full length human beta2GPI (wild-type), were used in competition assays to inhibit the autoantibodies from binding to immobilized wild-type beta2GPI. Only those domain-deleted mutants that contained domain 1 inhibited the binding to immobilized wild-type beta2GPI from all of the patients. The domain-deleted mutants that contained domain 1 inhibited all aCL in a similar but not identical pattern, suggesting that these aCL recognize a similar, but distinguishable, epitope(s) present on domain 1.
抗心磷脂（aCL）自身抗体与血栓形成、反复流产和血小板减少有关。只有在自身免疫性疾病中发现的aCL需要磷脂结合血浆蛋白β2糖蛋白I（β2GPI）参与抗体结合，现在被称为抗β2GPI。为了更好地理解与aCL相关的病理生理学，对从11例高滴度患者中亲和纯化的aCL的抗原特异性进行了评估。使用7种不同的人β2GPI重组结构域缺失突变体和全长人β2GPI（野生型）进行竞争试验，以抑制自身抗体与固定化野生型β2GPI结合。只有那些包含结构域1的结构域缺失突变体才能抑制所有患者的自身抗体与固定化野生型β2GPI的结合。包含结构域1的结构域缺失突变体以相似但不完全相同的模式抑制所有aCL，这表明这些aCL识别存在于结构域1上的相似但可区分的表位。
Zotero 插件